NYSE:NUVB Nuvation Bio Q3 2024 Earnings Report $6.57 -0.03 (-0.45%) As of 03:58 PM Eastern ProfileEarnings HistoryForecast Nuvation Bio EPS ResultsActual EPS-$0.15Consensus EPS -$0.13Beat/MissMissed by -$0.02One Year Ago EPSN/ANuvation Bio Revenue ResultsActual Revenue$0.73 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANuvation Bio Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateTuesday, November 5, 2024Conference Call Time6:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nuvation Bio Earnings HeadlinesHC Wainwright Weighs in on Nuvation Bio Q1 EarningsAugust 10 at 1:43 AM | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)August 7 at 12:22 AM | theglobeandmail.comSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices.August 10 at 1:00 AM | Freedom Financial (Ad)Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comNuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 6, 2026 | prnewswire.comDo IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy?August 5, 2026 | finance.yahoo.comSee More Nuvation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email. Email Address About Nuvation BioNuvation Bio (NYSE:NUVB) is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies. The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors. Nuvation Bio emphasizes a translational science approach, using biomarker strategies and patient-selection criteria to guide trial design and optimize the likelihood of clinical success. Its scientists leverage process chemistry expertise to streamline manufacturing and ensure scalable drug supply. Headquartered in New York, Nuvation Bio conducts global development activities through collaborations with leading academic centers, clinical research organizations, and commercial partners. The company’s leadership team brings extensive experience in drug discovery, translational research, and clinical development from both large pharmaceutical companies and emerging biotechnology firms. Adopting a capital-efficient operating model, Nuvation Bio balances in-house capabilities with strategic outsourcing to manage costs and accelerate timelines. With its focused pipeline and integrated development infrastructure, the company seeks to address critical unmet needs in oncology and advance novel therapies that have the potential to improve patient outcomes.View Nuvation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat5 Stocks the Market Rewarded After Strong Earnings ResultsQuantum Earnings Week: Winners and Losers Are Finally EmergingMarketBeat Week in Review – 08/03 - 08/07Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of WarCloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in FocusIs Monster Beverage’s Best-Case Scenario Already Priced Into the Stock? Upcoming Earnings SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
